Tricyclic thiazoles are a new class of angiogenesis inhibitors

Bioorg Med Chem Lett. 2013 May 1;23(9):2733-7. doi: 10.1016/j.bmcl.2013.02.067. Epub 2013 Feb 24.

Abstract

Tricyclic thiazoleamine derivatives that were identified as hits in a screen against human umbilical vein endothelial cell proliferation were subjected to a structure-activity relationship study. Two structurally superimposable scaffolds-4H-thiochromeno[4,3-d]thiazol-2-amine and 5,6-dihydro-4H-benzo[6,7]cyclohepta[1,2-d]thiazol-2-amine derivatives-yielded low-micromolar inhibitors, and two among them 37 and 43 also exhibited antiangiogenic activity in an endothelial tube formation assay. Thus, 37 and 43 can serve as leads to develop a novel class of antiangiogenic agents.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Angiogenesis Inhibitors / chemical synthesis
  • Angiogenesis Inhibitors / chemistry*
  • Angiogenesis Inhibitors / pharmacology
  • Cell Proliferation / drug effects
  • Cyclization
  • HeLa Cells
  • Human Umbilical Vein Endothelial Cells
  • Humans
  • Jurkat Cells
  • Structure-Activity Relationship
  • Thiazoles / chemical synthesis
  • Thiazoles / chemistry*
  • Thiazoles / pharmacology

Substances

  • Angiogenesis Inhibitors
  • Thiazoles